SloveniaTuberculosis profile
Population  2016 2.1 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.013 (0.013–0.013) 0.61 (0.61–0.62)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.01 (0.01–0.01)
Incidence  (includes HIV+TB) 0.14 (0.12–0.16) 6.5 (5.6–7.5)
Incidence (HIV+TB only) <0.01 (<0.01–<0.01) 0.05 (0.03–0.08)
Incidence (MDR/RR-TB)** 0 (0–0) 0 (0–0)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.039 (0.033–0.045) 0.045 (0.038–0.052)
Males <0.01 (<0.01–<0.01) 0.084 (0.072–0.097) 0.091 (0.077–0.1)
Total 0.012 (0.01–0.014) 0.12 (0.1–0.14) 0.14 (0.12–0.16)
TB case notifications, 2016  
Total cases notified 118
Total new and relapse 118
          - % tested with rapid diagnostics at time of diagnosis 52%
          - % with known HIV status 81%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 93%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.1 (0.08–0.11)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 1 1%
          - on antiretroviral therapy 1 100%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  0
(0–0)
Estimated % of TB cases with MDR/RR-TB 0% (0–3.9) 0% (0–71)  
% notified tested for rifampicin resistance 93% 80% 109
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 81% 129
Previously treated cases, excluding relapse, registered in 2015 100% 1
HIV-positive TB cases registered in 2015   0
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-01-16 Data: www.who.int/tb/data